J Dermatolog Treat. 2025 Dec;36(1):2560505. doi: 10.1080/09546634.2025.2560505. Epub 2025 Sep 29.
ABSTRACT
BACKGROUND: Vunakizumab (anti-interleukin-17A antibody) has shown favorable efficacy and safety in treating moderate-to-severe plaque psoriasis. The morbidity and severity of psoriasis vary in different regions of China.
OBJECTIVE: This post-hoc exploratory analysis aims to investigate the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis across different regions of China.
METHODS: This post-hoc exploratory analysis used data from a phase III trial (NCT04839016), with 461 patients receiving vunakizumab categorized into North (n = 118), Central (n = 252), and South (n = 91) China groups.
RESULTS: Psoriasis area and severity index (PASI)75/90/100 and static physician’s global assessment (sPGA) 0/1 response rates were similar among the three groups at week 12 (W12). Additionally, W12-W52 sustained PASI 75/90/100 and sPGA 0/1 response rates were also similar among groups. Similar improvements in patient-reported outcomes, including dermatology life quality index, itch-numerical rating scale, EuroQol-5D, and short form-36, were observed in the three groups. The incidence of adverse events was 80.5%, 90.1%, and 90.1% in the North, Central, and South China groups, respectively.
CONCLUSION: The efficacy and safety of vunakizumab are not affected by different regions of China in patients with moderate-to-severe plaque psoriasis.
PMID:41020409 | DOI:10.1080/09546634.2025.2560505
